SynthesisNuclear medicine communications2020
Performance of 68Ga-DOTA-SST PET/CT, octreoscan SPECT/CT and 18F-FDG PET/CT in the detection of culprit tumors causing osteomalacia: a meta-analysis.
Synthesis in Nuclear medicine communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 49 citations in OpenAlex.
- Beyond DOTATATE: [European journal of nuclear medicine and molecular imaging · 2026Article
- Imaging findings in the head and neck of phosphaturic mesenchymal tumors.Neuroradiology · 2026Article
- Burosumab for X-linked Hypophosphataemia and Tumour-induced Osteomalacia in Adults.TouchREVIEWS in endocrinology · 2026Review
- Article
- Autoimmune osteomalacia: a novel FGF23-related hypophosphatemic osteomalacia.Journal of bone and mineral metabolism · 2026Review
- Article
- A 65-year-old male with phosphaturic mesenchymal tumor presenting as tumor-induced osteomalacia: a case report.Annals of medicine and surgery (2012) · 2026Article
- Surgical Treatment for Osteomalacia Induced by Causative Tumor in the Knee Joint Region: A Single-Center Retrospective Clinical Study Over 10 Years.Orthopaedic surgery · 2025Article
- Diagnosis and Management of Hypophosphatemic Disorders.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2025Review
- X-linked hypophosphatemia and tumor-induced osteomalacia: a narrative review and expert opinion on the diagnostic and therapeutic challenges in the era of burosumab.Orphanet journal of rare diseases · 2025Review
- Postoperative outcome and clinical management of tumor-induced osteomalacia: a single-center retrospective cohort study on 117 patients.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025Article
- Failure of femoral internal fixation device secondary to phosphaturic mesenchymal tumor: a case report and literature review.BMC musculoskeletal disorders · 2025Review
- Unmasking Skull Base Phosphaturic Mesenchymal Tumors: A Rare and Treatable Cause of Tumor-Induced Osteomalacia.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2025Article
- Gallium-68-DOTATATE PET/CT for phosphaturic mesenchymal tumor localization in suspected tumor-induced osteomalacia.JBMR plus · 2025Article
- Successful cryoablation for a phosphaturic mesenchymal tumor in the maxilla causing tumor-induced osteomalacia: a case report.Archives of osteoporosis · 2025Article
- Orthopedic surgical treatment of osteomalacia induced by culprit soft tissue tumor in the hip region: a single-center retrospective study.BMC musculoskeletal disorders · 2025Article
- Unusual Association of Partial Fanconi Syndrome and Tumor-Induced Osteomalacia Revealed by Multiple Vertebral Fractures.Calcified tissue international · 2025Article
- Acquired hypophosphatemic osteomalacia: case series from a Peruvian referral center (1999-2023).Archives of osteoporosis · 2024Article
- Osteolytic mystery: A rare case of pathologic fracture from a phosphaturic mesenchymal tumor in hip and femur.Radiology case reports · 2024Article
- Diagnostic approach to rickets: an Endocrine Society of Bengal (ESB) consensus statement.Annals of pediatric endocrinology & metabolism · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe objective of this study was to assess and compare the performance of Ga-DOTA-conjugated-somatostatin-receptor-targeting-peptides (Ga-DOTA-SST) PET/CT, octreoscan-SPECT/CT and F-FDG-PET/CT in the detection of tumor-induced osteomalacia (TIO).
methodsRelevant studies reporting the performance Ga-DOTA-SST PET/CT, octreoscan-SPECT/CT and F-FDG-PET/CT in TIO were identified by searching PubMed, EMBASE, and Web of Science (last updated June 2019). Two authors independently extracted the numbers of true and false positives, and true and false negatives. The pooled estimates on a per-patient basis were calculated with 95% confidence interval (CI) obtained using a random-effects model.
resultsFourteen studies comprising 346 patients were included in this meta-analysis. The meta-analysis provided the following results on a per-patient analysis. The pooled sensitivities of both Ga-DOTA-SST PET/CT (90%, 95% CI 82-95%) and octreoscan-SPECT/CT (83%, 95% CI 75-89%) were found to be significantly higher (P < 0.005) than that of F-FDG PET/CT (67%, 95% CI 53-80%). There was no statistically significant difference between the sensitivity of Ga-DOTA-SST PET/CT and octreoscan-SPECT/CT (P = 0.161). Owing to the low number of articles with true negative findings, the pooled specificities were not calculated. A total of 287 tumors were identified in 287 patients according to the data the included studies offered. The majority of the tumors were located in the lower extremities (59.6%, 171/287), followed by craniofacial regions (24.0%, 69/287), torso (9.4%%, 27/287), and upper extremities (6.9%, 20/287).
conclusionThis meta-analysis demonstrates that somatostatin receptor-based imaging modalities outperformed F-FDG PET/CT in the detection of TIO, with Ga-DOTA-SST PET/CT performing slightly better than octreoscan-SPECT/CT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.